Drugs / CAP-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04704323 | Sep 2021 → Jan 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Catapult Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAP-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04704323 ↗ |
| Action | Deplete | “eliminate CCR7-positive leukemia cells via ADCC” NCT04704323 ↗ |
| Route | Intravenous | “receive intravenous \[IV\] administrations of escalating doses of CAP-100.” NCT04704323 ↗ |
| Target | CCR7 | “eliminate CCR7-positive leukemia cells via ADCC” NCT04704323 ↗ |